Recent Study: Singapore Pharmaceuticals & Healthcare Report Q1 2014

The island state's consistent investment in research and development, coupled with the government's increased commitment to healthcare, will provide pharmaceutical firms opportunities -especially in light of the ageing population. Nevertheless we highlight that Singapore's small population will continue to limit the pharmaceutical market's long-term growth potential.

Headline Expenditure Projections

* Pharmaceuticals: SGD940mn (US$770mn) in 2012 to SGD1.0bn (US$790mn) in 2013; +4.9% in local currency terms and +3.3% in US dollar terms. Forecast broadly in line with Q413.
* Healthcare: SGD16.2bn (US$13.2bn) in 2012 to SGD17.8bn (US$14.2bn) in 2013; +9.4% in local currency terms and +7.7% in US dollar terms. Forecast broadly in line with Q413.

Full Report Details at
- http://www.fastmr.com/prod/754662_singapore_pharmaceuticals_healthcare_report_q1.aspx?afid=303

Risk/Reward Ratings

Singapore's Pharmaceutical Risk/Reward Rating (RRR) score for Q114 is 62.1 out of the maximum 100 under our newly improved RRR system. The country scored above average for the majority of indicators and sub-indicators, including sector value growth, pensionable population and overall economic and political landscape. With the relatively high score, the country is ranked sixth out of the 19 key markets in the region, behind developed countries like Japan, South Korea and Australia, as well as emerging markets like China and Taiwan. In the South East Asia region, it continues to rank first due to its relatively higher score under country and industry risks.

Key Trends And Developments

* In October, two units under Singapore's Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC; A*STAR's technology transfer arm) and Exploit Technologies signed a joint research collaboration agreement with AstraZeneca to develop drugs to treat gram-negative bacterial infections. This new deal aims to reverse the global rise of antibiotic resistance.
* In September 2013, Japanese pharmaceutical company Mitsubishi Tanabe announced plans to open a new office. The office will assume responsibility for the company's operations in Singapore, which were previously handled by Mitsubishi Tanabe's Indonesian office. The company's Indonesian office will focus its energies instead on acting as a manufacturing base for the company's wider operations in South East Asia.
* Proceeding with the promise to increase the government's commitment to healthcare, during his National Day Rally, in August 2013 Singapore's Prime Minister Lee Hsien Loong announced a range of healthcare initiatives to increase patients' access to healthcare and insurance coverage.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Malaysia Pharmaceuticals & Healthcare Report Q1 2014
- Russia Pharmaceuticals & Healthcare Report Q1 2014
- Sweden Pharmaceuticals & Healthcare Report Q1 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2014
- Estonia Pharmaceuticals & Healthcare Report Q1 2014